BJP Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Corrections
Right arrow A corrigendum has been published
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavazzoni, P.
Right arrow Articles by Buse, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavazzoni, P.
Right arrow Articles by Buse, J.
The British Journal of Psychiatry (2004) 184: s94-S101
© 2004 The Royal College of Psychiatrists

Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications

Patrizia Cavazzoni, MD, Nitai Mukhopadhyay, PhD, Christopher Carlson, PhD and Alan Breier, MD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

John Buse, MD PhD

Division of General Medicine and Clinical Epidemiology and of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

Correspondence: Dr Patrizia Cavazzoni, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Tel: (317) 433 9485; fax: (317) 276 8682; e-mail: p_cavazzoni{at}lilly.com

Declaration of interest The study was sponsored by Eli Lilly and Company.

Aims In this retrospective analysis, we assessed the short-term risk of treatment-emergent diabetes (TED) among patients with schizophrenia during clinical trials of antipsychotic medications.

Method From a non-diabetic cohort of patients with schizophrenia (n=5013), the relationship between baseline non-fasting glucose measurement, presence at baseline of risk factors for diabetes, weight gain and therapy assignment on the risk of treatment-emergent diabetes were assessed.

Results At the baseline assessment, about a third of patients identified with TED during treatment had non-fasting glucose levels over 7.8 mmol/l and two-thirds had multiple diabetes risk factors. Both baseline non-fasting glucose level and the presence of multiple pre-existing diabetes risk factors appeared to have a major impact on the risk of developing diabetes.

Conclusions Overall, risk factors for diabetes in patients with schizophrenia overlap those in the general population. The results also suggest that many patients identified with TED might have had pre-existing glycaemic abnormalities or a high baseline burden of diabetes risk factors.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
T. G. Dinan
Introduction
The British Journal of Psychiatry, April 1, 2004; 184(47): s53 - s54.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 2004 The Royal College of Psychiatrists.